Skip to main content
SOMNOMED LIMITED logo

SOMNOMED LIMITED — Investor Relations & Filings

Ticker · SOM ISIN · AU000000SOM1 LEI · 529900NFR8QFOLJGP577 ASX Manufacturing
Open in API
Filings indexed 982 across all filing types
Latest filing 2026-03-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SOM

About SOMNOMED LIMITED

https://somnomed.com

SomnoMed Limited specializes in the development and manufacture of diagnostic and treatment solutions for sleep-related breathing disorders, primarily obstructive sleep apnea (OSA). The company is recognized for its Continuous Open Airway Therapy (COAT), which utilizes custom-fitted oral appliances to maintain an open airway during sleep. Its flagship product line, SomnoDent, offers a range of mandibular advancement devices designed to improve patient compliance and comfort compared to traditional continuous positive airway pressure (CPAP) therapy. SomnoMed focuses on clinical research and technological innovation to provide effective, non-invasive alternatives for patients suffering from mild to moderate OSA and snoring. The company serves a global market, collaborating with sleep dentists and physicians to deliver personalized treatment options that enhance long-term health outcomes and quality of life for individuals with sleep-disordered breathing.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - SOM 8 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted equity securities under an employee incentive scheme by SomnoMed Limited. It includes specifics such as security codes, issue dates, quantities, and references to ASX listing rules. The content is focused on notifying the market about the issuance of securities rather than reporting financial results or other types of corporate filings. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or other capital changes. The document length (6519 characters) and detailed issuance data support this classification rather than a brief announcement or a regulatory filing fallback.
2026-03-19 English
Application for quotation of securities - SOM 8 pages 20.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement related to the application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue dates, and classifications, but it does not contain financial statements, earnings data, or management discussion. It is a regulatory announcement about securities quotation rather than a financial report or earnings release. This type of document fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital changes.
2026-03-17 English
Notification of cessation of securities - SOM 5 pages 16.2KB
Regulatory Filings Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for SomnoMed Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a regulatory announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any form of detailed financial or governance report. Instead, it is a formal notification to the ASX about changes in the company's securities. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-03-08 English
Application for quotation of securities - SOM 8 pages 20.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from SomnoMed Limited regarding the application for quotation of securities on the ASX. It details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue dates, and classifications. This type of document is a formal announcement related to new securities being quoted on the exchange, which aligns with announcements about share issues or capital changes. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (6904 characters) and content confirm it is a full announcement, not just a brief notice or certification.
2026-03-08 English
Half Yearly Report and Accounts 21 pages 840.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D and Half-Year Financial Report 31 December 2025' and is an ASX announcement dated 27 February 2026. It includes detailed financial statements such as the consolidated statement of profit or loss, financial position, changes in equity, and cash flows for the half-year ended 31 December 2025. It also contains a directors' report, auditor's independence declaration, and notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2026
2026-02-26 English
Half year results announcement FY26 4 pages 583.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'SomnoMed 1H FY26 Half Year Results' and provides detailed financial data for the half year ended 31 December 2025. It includes revenue figures, EBITDA, capex, cash flow, segment performance, operational highlights, and leadership appointments. The content is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is 8212 characters long, which is sufficient to be a full report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification. Therefore, the correct classification is IR with high confidence. H1 2026
2026-02-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.